Energy News / Shareholders Foundation, Inc.

NASDAQ:ZGNX Shareholder Notice: Lawsuit Alleges Misleading Statements by Zogenix, Inc.

Via: ReleaseWire

Updated 12:15 PM CDT, Tue, April 23,2019

A lawsuit was filed for Investors of Zogenix (NASDAQ: ZGNX) shares of over alleged violations of Federal Securities Laws by Zogenix, Inc.

San Diego, CA -- (SBWIRE) -- 04/23/2019 -- An investor, who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX), filed a lawsuit over alleged violations of Federal Securities Laws by Zogenix, Inc. in connection with certain allegedly false and misleading statements made between February 6, 2019 and April 8, 2019.

Investors who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) between February 6, 2019 and April 8, 2019, and / or if you purchased any NASDAQ: ZGNX shares prior to February 2019 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: June 11, 2019. NASDAQ: ZGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On April 8, 2019, Zogenix, Inc. announced it received a refusal to file letter from the U.S. Food and Drug Administration ("FDA") regarding Zogenix's new drug application ("NDA") for FINTEPLA, Zogenix's proposed treatment for seizures associated with Dravet syndrome. Zogenix, Inc. told investors that "the FDA determined that the NDA... was not sufficiently complete to permit a substantive review... [F]irst, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA."

The plaintiff claims that between February 6, 2019 and April 8, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Zogenix's NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset, that consequently, Zogenix's NDA for FINTEPLA was unlikely to gain FDA approval, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqzgnx-shareholder-notice-lawsuit-alleges-misleading-statements-by-zogenix-inc-1201876.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com